Skip to main content
Premium Trial:

Request an Annual Quote

ABL Diagnostics, Palex Sign MDx Distribution Deal for Spain

NEW YORK – French company Advanced Biological Laboratories Diagnostics said Monday that it has signed a distribution agreement that gives Palex the rights to distribute ABL's molecular assays and software to microbiology laboratories in Spain.

Under the agreement, Palex will have the rights to distribute ABL's products such as its next-generation sequencing kits and software systems and its Sanger sequencing-based sequencing products. The deal includes the distribution of ABL's DeepChek line of sequencing-based assays. ABL also offers its UltraGene series of PCR-based assays, the company said in a statement.

ABL's CE-IVD-marked assays include tests for HIV, SARS-CoV-2, tuberculosis, and hepatitis B and C.

The firms said that the deal will be carried out in collaboration with ABL affiliate ABL TherapyEdge SL Spain. Financial and other terms of the deal were not disclosed.

"Through its network of suppliers, Palex can offer end-to-end solutions to hospitals and laboratories involved in infectious diseases management," Palex In Vitro Diagnostic Manager Jaune Clariana said in a statement. "This collaboration with ABL Diagnostics and its Spanish affiliate is a strategic asset for the company."

ABL also entered an agreement last month with AB Analitica to commercialize ABL's microbiology genotyping solutions in Italy.